Skip to main content

Table 1 Relationship between clinicopathological factors and mRNA expression of VEGF-C

From: Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis

   

VEGF-C expression

 
  

case

mean

± sd

p-value

age

≧65

44

-0.074

± 0.6

0.73

 

< 65

62

0.16

± 0.66

 

gender

male

87

0.066

± 0.65

0.06

 

female

19

0.037

± 0.63

 

Tfactor

Tis

5

-0.021

± 0.14

 
 

T1

12

0.11

± 0.34

 
 

T2

11

-0.098

± 0.42

 
 

T3

33

-0.038

± 0.7

 
 

T4

17

0.218

± 1.0

 

Tis, T1 vs T2-T4

   

0.8

Nfactor

N0

29

-0.049

± 0.37

 
 

N1

77

0.1

± 0.72

0.28

Stage

Stage0

6

-0.23

± 0.14

 
 

Stage1

6

-0.072

± 0.35

 
 

Stage2A

13

-0.09

± 0.31

 
 

Stage2B

17

0.061

± 0.47

 
 

Stage3

30

0.085

± 0.66

 
 

Stage4

11

-0.19

± 1

 
 

Stage4A

23

0.34

± 0.73

 

Stage0-2A vs Stage2B-4A

   

0.049

Histrogical Type

    
 

well

41

0.092

± 0.57

 
 

moderate

56

0.053

± 0.75

 
 

poor

9

-0.087

± 0.19

 

well vs moderate · poor

   

0.34

lymphatic invasion

    
 

positive

69

0.056

± 0.72

0.61

 

negative

37

0.07

± 0.47

 

vein invasion

    
 

positive

54

0.024

± 0.78

0.22

 

negative

52

0.098

± 0.47

 
  1. The expression of VEGF-C is higher in Stage2B-4A patients than in Stage0-2A patients